Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction

MLA

Ofri Mosenzon, et al. “Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.” Circulation, vol. 139, May 2019, pp. 2516–27. EBSCOhost, https://doi.org/10.1161/circulationaha.119.039996.

APA

Ofri Mosenzon, Lawrence A. Leiter, Stephen D. Wiviott, Christian T. Ruff, Remo H.M. Furtado, Thomas A Zelniker, Martin Fredriksson, Itamar Raz, Marc P. Bonaca, Anna Maria Langkilde, Julia F Kuder, Avivit Cahn, Ingrid Gause-Nilsson, Jose C. Nicolau, John P.H. Wilding, Deepak L. Bhatt, Darren K. McGuire, Sabina A. Murphy, & Marc S. Sabatine. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 139, 2516–2527. https://doi.org/10.1161/circulationaha.119.039996

Chicago

Ofri Mosenzon, Lawrence A. Leiter, Stephen D. Wiviott, Christian T. Ruff, Remo H.M. Furtado, Thomas A Zelniker, Martin Fredriksson, et al. 2019. “Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.” Circulation 139 (May): 2516–27. doi:10.1161/circulationaha.119.039996.